Published in Physician Business Week, November 25th, 2008
The Company reported a net loss of $1.6 million, or $(.05) per basic and diluted common share, for the third quarter of 2008 compared to a net loss of $1.1 million, or $(.04) per basic and diluted common share, for the same period last year.
"Collaborations are an important element of Interleukin Genetics' strategic plan to distribute and develop new, high value genetic tests, and we were pleased to lay significant groundwork for new partnerships this quarter," commented Lewis H. Bender, Chief Executive Officer. "Our revised...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.